Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 578

1.

Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials.

Costa APF, Cobucci RNO, da Silva JM, da Costa Lima PH, Giraldo PC, Gonçalves AK.

J Immunol Res. 2017;2017:3736201. doi: 10.1155/2017/3736201. Epub 2017 Jul 24. Review.

PMID:
28812030
2.

Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review.

Maver PJ, Poljak M.

Vaccine. 2017 Aug 8. pii: S0264-410X(17)31064-2. doi: 10.1016/j.vaccine.2017.07.113. [Epub ahead of print]

PMID:
28801154
3.

Major Birth Defects after Vaccination Reported to the Vaccine Adverse Event Reporting System (VAERS), 1990 to 2014.

Moro PL, Cragan J, Lewis P, Sukumaran L.

Birth Defects Res. 2017 Jul 17;109(13):1057-1062. doi: 10.1002/bdr2.23622.

PMID:
28762675
4.

Text message reminders for vaccination of adolescents with chronic medical conditions: A randomized clinical trial.

Hofstetter AM, Barrett A, Camargo S, Rosenthal SL, Stockwell MS.

Vaccine. 2017 Jul 20. pii: S0264-410X(17)30920-9. doi: 10.1016/j.vaccine.2017.07.022. [Epub ahead of print]

PMID:
28736201
6.

Acceptability of multipurpose human papillomavirus vaccines among providers and mothers of adolescent girls: A mixed-methods study in five countries.

Vielot NA, Goldberg SK, Zimet G, Smith SB, Anne McDonald M, Ramos S, Morgan K, Joo Kim C, Richter KL, Peris M, Whaley KJ, Smith JS.

Papillomavirus Res. 2017 Jun;3:126-133. doi: 10.1016/j.pvr.2017.04.001. Epub 2017 Apr 6.

7.

A Genetically Modified attenuated <i>Listeria</i> Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner.

Jia YY, Tan WJ, Duan FF, Pan ZM, Chen X, Yin YL, Jiao XA.

Front Cell Infect Microbiol. 2017 Jun 29;7:279. doi: 10.3389/fcimb.2017.00279. eCollection 2017.

8.

Safety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studies.

Ogawa Y, Takei H, Ogawa R, Mihara K.

J Pharm Health Care Sci. 2017 Jul 11;3:18. doi: 10.1186/s40780-017-0087-6. eCollection 2017.

9.

Expanded strain coverage for a highly successful public health tool: prophylactic 9-valent human papillomavirus vaccine.

Zhang Z, Zhang J, Xia N, Zhao Q.

Hum Vaccin Immunother. 2017 Jul 12:0. doi: 10.1080/21645515.2017.1346755. [Epub ahead of print]

PMID:
28699820
10.

Leveraging machine learning-based approaches to assess human papillomavirus vaccination sentiment trends with Twitter data.

Du J, Xu J, Song HY, Tao C.

BMC Med Inform Decis Mak. 2017 Jul 5;17(Suppl 2):69. doi: 10.1186/s12911-017-0469-6.

11.

Safety and perception: What are the greatest enemies of HPV vaccination programmes?

Bonanni P, Zanella B, Santomauro F, Lorini C, Bechini A, Boccalini S.

Vaccine. 2017 Jun 10. pii: S0264-410X(17)30730-2. doi: 10.1016/j.vaccine.2017.05.071. [Epub ahead of print]

PMID:
28610824
12.

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.

Huang LM, Puthanakit T, Cheng-Hsun C, Ren-Bin T, Schwarz T, Pellegrino A, Esposito S, Frenette L, McNeil S, Durando P, Rheault P, Giaquinto C, Horn M, Petry KU, Peters K, Azhar T, Hillemanns P, De Simoni S, Friel D, Pemmaraju S, Hezareh M, Thomas F, Descamps D, Folschweiller N, Struyf F.

J Infect Dis. 2017 Jun 7. doi: 10.1093/infdis/jix154. [Epub ahead of print]

PMID:
28591778
13.

Committee Opinion No. 704 Summary: Human Papillomavirus Vaccination.

[No authors listed]

Obstet Gynecol. 2017 Jun;129(6):1155-1156. doi: 10.1097/AOG.0000000000002111.

PMID:
28538494
14.

Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation.

Sun Y, Peng S, Yang A, Farmer E, Wu TC, Hung CF.

Gene Ther. 2017 Jul;24(7):408-415. doi: 10.1038/gt.2017.38. Epub 2017 May 11.

PMID:
28492521
15.

Improving Human Papillomavirus Vaccine Use in an Integrated Health System: Impact of a Provider and Staff Intervention.

McLean HQ, VanWormer JJ, Chow BDW, Birchmeier B, Vickers E, DeVries E, Meyer J, Moore J, McNeil MM, Stokley S, Gee J, Belongia EA.

J Adolesc Health. 2017 Aug;61(2):252-258. doi: 10.1016/j.jadohealth.2017.02.019. Epub 2017 Apr 24.

16.

School nurses' attitudes towards and experiences of the Swedish school-based HPV vaccination programme - A repeated cross sectional study.

Grandahl M, Larsson M, Tydén T, Stenhammar C.

PLoS One. 2017 Apr 18;12(4):e0175883. doi: 10.1371/journal.pone.0175883. eCollection 2017.

17.

Major Birth Defects after Vaccination Reported to the Vaccine Adverse Event Reporting System (VAERS), 1990 to 2014.

Moro PL, Cragan J, Lewis P, Sukumaran L.

Birth Defects Res. 2017 Apr 11. doi: 10.1002/bdra.23622. [Epub ahead of print]

PMID:
28398711
18.

Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes.

Scheller NM, Pasternak B, Mølgaard-Nielsen D, Svanström H, Hviid A.

N Engl J Med. 2017 Mar 30;376(13):1223-1233. doi: 10.1056/NEJMoa1612296.

PMID:
28355499
19.

Committee Opinion No. 704: Human Papillomavirus Vaccination.

Immunization Expert Work Group, Committee on Adolescent Health Care.

Obstet Gynecol. 2017 Jun;129(6):e173-e178. doi: 10.1097/AOG.0000000000002052.

PMID:
28346275
20.

Human papillomavirus first and second generation vaccines-current status and future directions.

Pouyanfard S, Müller M.

Biol Chem. 2017 Jul 26;398(8):871-889. doi: 10.1515/hsz-2017-0105. Review.

PMID:
28328521

Supplemental Content

Loading ...
Support Center